Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy-Reference-Cited by-同舟云学术

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

Published:2021-10-27 Issue:4 Volume:128 Page:719-726
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Perrino Matteo¹,De Pas Tommaso²,Bozzarelli Silvia¹,Giordano Laura³,De Vincenzo Fabio¹,Conforti Fabio²^ORCID,Digiacomo Nunzio¹,Cordua Nadia⁴,D'Antonio Federica⁴,Borea Federica⁴,Santoro Armando¹⁴,Zucali Paolo Andrea¹⁴^ORCID

Affiliation:

1. Department of Oncology IRCCSHumanitas Research Hospital Milan Italy

2. Department of Oncology IRCCSEuropean Institute of Oncology Milan Italy

3. Biostatistic Unit IRCCSHumanitas Research Hospital Milan Italy

4. Department of Biomedical Sciences Humanitas University Milan Italy

Funder

Bayer HealthCare

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33990

Reference42 articles.

1. Epidemiology of Thymoma and Associated Malignancies

2. Reproducibility of the WHO classification of thymomas: Practical implications

3. Follow-up study of thymomas with special reference to their clinical stages

4. Thymic Malignancies: From Clinical Management to Targeted Therapies

5. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671);Annals of Oncology;2024-09

4. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study;JCO Precision Oncology;2024-04

5. What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas—Current Status and Future Directions?;Cancers;2024-01-18